



Institutional Biosafety Committee (IBC)
Zoom Meeting Minutes
23 March 2026
9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:

Dr. [REDACTED] (EC)
 Dr. [REDACTED] (HD)
 Dr. [REDACTED] (PD)
 Dr. [REDACTED] (MF)
 Dr. [REDACTED] (LH)
 Dr. [REDACTED] (BH)
 Dr. [REDACTED] (MJ)
 [REDACTED] (EK)
 Dr. [REDACTED] (SK)
 Dr. [REDACTED] (AL)*
 Dr. [REDACTED] (JL)
 Dr. [REDACTED] (CM)
 Dr. [REDACTED] (SM)
 Dr. [REDACTED] (Co-chair) (BM)
 Dr. [REDACTED] (Co-chair) (TM)
 Dr. [REDACTED] (MV)
 [REDACTED] (ZJW)
 [REDACTED] (ZW)

Non-voting IBC Members/Guests:

[REDACTED] (AA)
 [REDACTED] (QB)
 [REDACTED] (JH)*
 [REDACTED] (JW)
 [REDACTED] (MW)
 [REDACTED] (CW)*
 [REDACTED] (SJ)**

I. Call to Order: 9:00am (Mountain Time)

II. Conflict of Interest:

- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

III. Review and Approval of Previous Minutes: 23 February 2026

The minutes were reviewed and approved by the IBC.

Approved = 17

Opposed = 0

Abstained = 1 (EC)

IV. IBC Administrative Business:

A. IBC Administrative Changes: None

B. Protocol Closures:

i. [REDACTED] - # 1329

ii. [REDACTED] - # 1587

C. Protocol Transfers: None

Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:

During the review, the IBC assessed the containment levels in addition to the facilities,



procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences, the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

V. New Business:

1. Environmental Health and Safety Office Updates:

- i. EC announced the upcoming retirement of the Associate Vice Chancellor for Research.
- ii. EC reminded community members that additional POI training may be required.

2. Biosafety Office Updates:

- i. BH announced the upcoming migration between IBC protocol management systems.
- ii. BH introduced to the committee a guest from CHCO.

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Yomogida, Kentaro - # 25-0039: *A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy*
2. Piquet, Amanda - # 24-1330: *A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Treatment Refractory Stiff Person Syndrome (KYSA-8)*
3. Patel, Sapna - # 25-0004: *A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma*
4. Taylor, Matthew - # 25-0602: *A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1*

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

1. Abbott, Kaleb - # 26-0186: A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects with Stage 2 or 3 Neurotrophic Keratitis

Biosafety level: BSL-2 with standard precautions

NIH Section(s): III-C

Approved = 18

Opposed = 0

Abstained = 0

The IBC protocol presented was deferred by the IBC. The IBC to review the protocol at a later IBC meeting with recommendations to address items including providing additional home administration details, clarifying dose discrepancy details, confirming route of IP administration/application, clarifying shipment of IP for home setting, updating PPE checkboxes, ensuring proper IP assessment, and ensuring that the application is properly signed and dated by the PI.

2. Faulk, Kelly - # 26-0369: A Single-Arm, Open-Label, Multicenter, Phase 1B/2 Study Evaluating the Safety and Efficacy of Auto1 in Pediatric Patients with CD19-Positive Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B ALL) and R/R Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL)

Biosafety level: BSL-2 with standard precautions



NIH Section(s): III-C

Approved = 18

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with no further committee concerns.

*JH, CW, and AL left the meeting at 9:32am.

VIII. New Laboratory Protocol Reviews:

1. [REDACTED] - # 1758: Overcoming therapeutic resistance in lung cancer

Biosafety level: BSL-2, ABSL-1

NIH Section(s): III-D-2, III-F

Approved = 17

Opposed = 0

Abstained = 0

The IBC protocol presented was deferred by the IBC. The IBC to review the protocol at a later IBC meeting with recommendations to address items including updating PPE details, further explaining procedure details, updating checkboxes for the *NIH Guidelines*, updating engineering control checkboxes, and clarifying use of recombinant products.

**SJ left the meeting at 9:45am

2. [REDACTED] - # 1744: Characterizing Mechanisms of Preleukemic Transformation

Biosafety level: BSL-2, BSL-1, ABSL-1

NIH Section(s): III-D-4, III-F

Approved = 16

Opposed = 0

Abstained = 1 (ZJW)

The IBC protocol presented was approved with the recommendation for modifications required to address items including updating details regarding the research narrative, protocol procedures, protocol checkboxes, use of animals, BSC certification, and biomaterial section.

IX. De Novo Laboratory Protocol Reviews:

1. [REDACTED] - # 1357: Viral Vector Mediated Gene Delivery in Rodent Optic nerve Regeneration Studies

Biosafety level: BSL-1, ABSL-1

NIH Section(s): III-D-4, III-F

Approved = 17

Opposed = 0

Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including selecting appropriate protocol checkboxes and adding a procedure.

2. [REDACTED] - # 1229: Drug and biomarker development in urological cancers

Biosafety level: BSL-2, ABSL-1

NIH Section(s): III-D-1, III-D-2, III-D-4, III-F

Approved = 17

Opposed = 0

Abstained = 0



The IBC protocol presented was approved with the recommendation to address minor administrative items including selecting appropriate protocol checkboxes and updating BSC details.

3. [REDACTED] - # 1626: **Mechanisms of cellular self-renewal**
Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-E-3, III-F
Approved = 17
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating protocol checkboxes, adding biomaterial details and procedures, and updating BSC details.
4. [REDACTED] - # 1642: **Lung cancer studies in the Pine lab**
Biosafety level: BSL-2, ABSL-2
NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
Approved = 17
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating agent details, clarifying generation of vectors, updating listed IACUC protocol expiration dates, updating the animal work and biomaterial sections, removing the obsolete Appendix T, and removing IACUC protocol-level detail.
5. [REDACTED] - # 1646: **Defining the Immune Mechanisms of Pediatric Cholestatic Liver Disease and Mouse Models of Obstructive Cholestasis**
Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
NIH Section(s): III-D-4, III-F
Approved = 17
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating research narrative details, BSLs, and protocol checkboxes.

X. Significant Amendment Reviews for Laboratory Protocols: None

XI. Exempt Protocols – New/Renewal:

1. [REDACTED] - # 1763: *Measurement of intracochlear pressures during noise exposure*
2. [REDACTED] - # 1421: *Randomized Trial of Diet in GDM: Metabolic Consequences for Mother and Offspring*

XII. Exempt Protocol Amendments:

1. [REDACTED] - # 1051: *Molecular Pathogenesis and Immunity of Arthropod-Borne Pathogens and other Virus Infections*
2. [REDACTED] - # 1671: *Mucosal eosinophil specialization and activation.*
3. [REDACTED] - # 1628: *Cancer- and chemotherapy-induced musculoskeletal defects*
4. [REDACTED] - # 1187: *Preparation of brain slices from naive rats and mice and rats subjected to early-life seizures*
5. [REDACTED] - # 1065: *Development and Homeostasis of innate T cells.*



University of Colorado
Anschutz Medical Campus

- XIII. **Additional Business:** None
- XIV. **Next Meeting Scheduled:** 27 April 2026, 9:00am (Mountain Time)
- XV. **Adjournment:** 10:35am (Mountain Time)